Meeting
2022 ASCO Annual Meeting
Artificial intelligence-powered pathology image analysis merged with spatial transcriptomics reveals distinct TIGIT expression in the immune-excluded tumor-infiltrating lymphocytes.
Authors
Gahee Park
Lunit Inc., Seoul, South Korea
Gahee Park , Sanghoon Song , Sukjun Kim , Sangheon Ahn , Hyunjoo Kim , Jaegeun Lee , Juneyoung Ro , Woomin Park , Taiwon Chung , Cholmin Kang , Chunggi Lee , Huijeong Kim , Jisoo Shin , Seungje Lee , Eunji Baek , Sumin Lee , Melody SeungHui Seo , Hyojung Choi , Donggeun Yoo , Chan-Young Ock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2570)
DOI
10.1200/JCO.2022.40.16_suppl.2570
Abstract #
2570
Poster Bd #
225
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Facile single cell profiling and clonotype analysis of NSCLC immune microenvironments.
First Author: Ameen Abdulla Salahudeen
Poster
2024 ASCO Annual Meeting
Pan-cancer B- and T-cell transcriptome analysis of CXCL13 as a predictive marker for immune checkpoint inhibitor response.
First Author: Yu Fujiwara
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A transcriptomic approach to explore the immune landscape of patient with pancreatic ductal adenocarcinoma with prognostic impact.
First Author: Jose Antonio Lopez Guerrero
Poster
2023 ASCO Annual Meeting
Relationship between tumor microenvironment (TME)-based histomic TGFβ signature (TGFBs), stromal fibroblast recruitment, and exclusion of immune cells as immunotherapy resistance mechanisms.
First Author: Gahee Park